|
Money1469 (der wohl sehr gut informiert ist) hat's die Tage drüben auf Yahoo auf dem Punkt gebracht, das Posting könnte ich mehrmals am Tag durchlesen wegen der klare Gedankenstruktur (nichtmal Schwartz's manachmal schlechte Führungsstil könnte die positve Ausgangslage -sprich GALE's Ausgangslage April 15- komplett wiederlegen) Why I hold GALE and continue to accumulate Share-- at requests of Jim As each day goes, and no negative news flow from validated sources about Gale's multiple trials the probability increases of a successful outcome. NeuVax would be the second vaccine to receive FDA approval in relation to cancer, most approvals deal with antibody, DNDN vaccine (provenge) was the first but lacked convenience to patients and it was too costly as well as significant side effects. NeuVax has: 1. Costs of production low 2. Patience convenience (big one) 3. Minimum side effects, just reddish to skin 4. Limited number of doctor's visits (11 times within 3yr period) 5. 3-years benefit to DFS (which will validated in this coming Dec/Jan) 6. NeuVax can work or will work within multiple cancer types in preventative fashion after standard care Now the Company Gale: 1. Gale has reconfigured it's management team with industry vets, CEO owns 415,000 shares +++warrants 2. Gale has obtained funding for all programs with partnerships with Roche, DOD, Dr. Redd 3. Gale has funding to support operations well into 2017 4. Most importantly, the Science is Sound and has never been challenged on validity 5. Blackrock significantly increased holding of Gale within the last 60 days 6. Abstrals revenues are increasing each quarter and is second in the market in EU- producing revenues 30-60 Million in the EU. Gale projection of 15-18 million is very conservative. For all of the above reasons, I continue to hold and accumulate shares. This is the forum in which I share my research, knowledge and excitement in hopes it will benefit others as well as myself. Always do your own DD, and remember FUD is a factor. http://finance.yahoo.com/mbview/threadview/?&bn=12a6b315-348… |
|
| aus der Diskussion: | Sellas Life Sciences Group (ehemals Galena Biopharma) |
| Autor (Datum des Eintrages): | Growth2012 (31.03.15 21:26:19) |
| Beitrag: | 879 von 2,935 (ID:49469216) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |